


| | |
|---|---|
|  | <p>Alameda Alliance for Health</p> <h1>FORMULARY UPDATE</h1> <p><u>Effective 05/01/2026, unless indicated below under Committee Actions.</u></p> |
|---|---|

Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions

The P&T Committee reviewed the efficacy, safety, cost, and utilization profiles of the following therapeutic categories and drug monographs at the March 17, 2026, meeting:

| Therapeutic/Monograph Class Reviews | |
|--|--|
| <ul style="list-style-type: none"> • Alcohol Use Disorder Agents Class Review • Cystic Fibrosis Agents Class Review • First Generation Antihistamines Class Review • Fluoride Dental Preparations Class Review | <ul style="list-style-type: none"> • Sickle Cell Disease Agents Class Review • Methergine Monograph • Insulins Class Review • Multiple Sclerosis Agents Class Review |

The P&T Committee approved the following modifications to the formulary for the Alliance’s Group Care programs.

| Generic//Biosimilar Name & Strength/Dosage Form | Brand Name | Committee Actions |
|---|---|---|
| <i>insulin glargine Soln Pen-Injector 300 Unit/ML (1 Unit Dial)</i> | Toujeo SoloStar Subcutaneous Solution Pen-injector 300 UNIT/ML | Add to Formulary (F) with Prior Authorization (PA) |
| <i>insulin glargine Soln Pen-Injector 300 Unit/ML (2 Unit Dial)</i> | Toujeo Max SoloStar Subcutaneous Solution Pen-injector 300 UNIT/ML | Add to F-PA |
| <i>insulin glargine Soln Pen-Injector 300 Unit/ML (1 Unit Dial)</i> | Toujeo SoloStar Subcutaneous Solution Pen-injector 300 UNIT/ML | Update to Non-formulary (NF) |
| <i>insulin glargine Soln Pen-Injector 300 Unit/ML (2 Unit Dial)</i> | Toujeo Max SoloStar Subcutaneous Solution Pen-injector 300 UNIT/ML | Update to NF |
| <i>nerandomilast Oral Tablet 9 MG</i> | Jascayd Oral Tablet 9 MG | Add to F-PA |
| <i>nerandomilast Oral Tablet 18 MG</i> | Jascayd Oral Tablet 18 MG | Add to F-PA |
| <i>insulin aspart protamine and insulin aspart 70/30 100 unit/mL injection suspension</i> | NovoLOG Mix 70/30 Subcutaneous Suspension (70-30) 100 UNIT/ML | Add to Formulary with Quantity Limit (F-QL) (30mL/30 days) |
| <i>insulin aspart protamine and insulin aspart mix 70/30 100 unit/mL pen</i> | NovoLOG Mix 70/30 FlexPen Subcutaneous Suspension Pen-injector (70-30) 100 UNIT/ML | Add to F-QL (30mL/30 days) |
| <i>ustekinumab-hmny Subcutaneous Solution Prefilled Syringe 90 MG/ML</i> | Starjemza Subcutaneous Solution Prefilled Syringe 90 MG/ML | Add to F-QL (Initial: 2 syringes (2mL)/28 days; Maintenance: 1 syringe (1mL)/56 days) |
| <i>ustekinumab-hmny Subcutaneous Solution 45 MG/0.5ML</i> | Starjemza Subcutaneous Solution 45 MG/0.5ML | Add to F-QL (Initial: 2 vials (1mL)/28 days; Maintenance: 1 vial (0.5mL)/84 days) |
| <i>ustekinumab-hmny Subcutaneous Solution Prefilled Syringe 45 MG/0.5ML</i> | Starjemza Subcutaneous Solution Prefilled Syringe 45 MG/0.5ML | Add to F-QL (Initial: 2 syringes (1mL)/28 days; Maintenance: 1 syringe (0.5mL)/84 days) |
| <i>ustekinumab-aauz Subcutaneous Solution Prefilled Syringe 90 MG/ML</i> | Otulfi Subcutaneous Solution Prefilled Syringe 90 MG/ML | Add to F-QL (Initial: 2 syringes (2mL)/28 days; Maintenance: 1 syringe (1mL)/56 days) |
| <i>ustekinumab-aauz Subcutaneous Solution Prefilled Syringe 45 MG/0.5ML</i> | Otulfi Subcutaneous Solution Prefilled Syringe 45 MG/0.5ML | Add to F-QL (Initial: 2 syringes (1mL)/28 days; Maintenance: 1 syringe (0.5mL)/84 days) |

| | | |
|---|--|--|
| <i>adalimumab-bwwd</i> Subcutaneous Solution Auto-injector 40 MG/0.4ML | Hadlima PushTouch Subcutaneous Solution Auto-injector 40 MG/0.4ML | Add to F-QL (Loading Dose: 3.2mL per 28 days; Maintenance: 1.6 ML per 28 days) |
| <i>adalimumab-bwwd</i> Subcutaneous Solution Prefilled Syringe 40 MG/0.4ML | Hadlima Subcutaneous Solution Prefilled Syringe 40 MG/0.4ML | Add to F-QL (Loading Dose: 3.2mL per 28 days; Maintenance: 1.6 ML per 28 days) |
| <i>enoxaparin sodium</i> Injection Solution 300 MG/3ML | Lovenox Injection Solution 300 MG/3ML | Add to Formulary (F) (Member allowed up to 2 fills per 365 days) |
| <i>ethynodiol diac-eth</i> estradiol Oral Tablet 1-35 MG-MCG | Valtva 1/35 Oral Tablet 1-35 MG-MCG | Add to F |
| <i>norgestrel-ethinyl estradiol</i> Oral Tablet 0.3-30 MG- MCG | Cryselle Oral Tablet 0.3-30 MG-MCG | Add to F |
| <i>theophylline ER Oral</i> Tablet Extended Release 12 Hour 100 MG | Theo-24 Oral Capsule Extended Release 24 Hour 100 MG | Add to F (allow 90-days supply) |
| <i>theophylline ER Oral</i> Tablet Extended Release 12 Hour 200 MG | Theo-24 Oral Capsule Extended Release 24 Hour 200 MG | Add to F (allow 90-days supply) |

PRIOR AUTHORIZATION GUIDELINE UPDATES

| | |
|--|---|
| Corlanor (ivabradine) | Injectable Anticoagulants |
| Corticosteroids for Duchenne Muscular Dystrophy (DMD) | Altoprev (lovastatin ER) and Fluvastatin, Fluvastatin ER |
| Brilinta (ticagrelor) tablet | GLP-1 Agonists |
| DPP-4 Inhibitors and Combinations | Pulmonary Biologics for Respiratory and Eosinophilic Conditions |
| Symlin (pramlintide) | Biologic Agents for Nasal Polyposis |
| Verquvo | Presbyopia Agents |
| Antifibrotic Respiratory Tract Agents | Specialty Biologic Agents |
| Tryngolza | Immunoglobulin A (IgA) Nephropathy Agents |
| GLP1 Receptor Agonists (Wegovy/Zepbound) for Non-Weight Loss Indications | Anti-Obesity Medications |

PRIOR AUTHORIZATION GUIDELINES REVIEWED (NO UPDATES)

| | |
|---|---|
| Angiotensin II Receptor Blockers and Renin Inhibitors | Atovaquone (Mepron) |
| Tadalafil (Cialis) for BPH | Elmiron (pentosane polysulfate sodium) |
| Ezetimibe (Zetia) | Inhaled Corticosteroids/Long-Acting Beta-Agonists (ICS/LABA) Combinations |
| Ophthalmic Antihistamines | Histamine H2 Receptor Antagonists |
| SGLT2 inhibitors and Combinations | Agents for Atopic Dermatitis |
| Parkinson's Disease Agents | Linezolid |
| Pyridostigmine (Mestinon) | Long-Acting Muscarinic /Long-Acting Beta Agonist/ Corticosteroid inhaled Triple |
| Corticosteroid Preparations to Treat Hemorrhoids | Fexofenadine-pseudoephedrine |
| Savella (milnacipran) tablet | Travoprost (Travatan Z) ophthalmic drops |
| Arikayce (amikacin) | Zurzuvae |
| Dificid | Niemann-Pick Disease Type C |

**For questions, please contact the Alliance's Pharmacy Services department at:
(510) 747-4541.**